Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study

E. E. Schaake, T. S. Aukema, J. S. Belderbos, W. Uyterlinde, N. van Zandwijk, R. A. Váldes Olmos, M. Verheij, Andrew Vincent, M. M. van den Heuvel

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

INTRODUCTION Despite the benefits from concurrent chemoradiotherapy (CCRT) regimens in patients with locally advanced non-small cell lung cancer (NSCLC), more efficacious treatment options are needed. Cetuximab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor, has demonstrated activity in patients with metastatic NSCLC. This study assessed whether combining cetuximab with CCRT is feasible. METHODS Patients with inoperable locally advanced NSCLC received cetuximab (400 mg/m2 on day 1, 250 mg/m2 q1w in weeks 2-6) in addition to radiotherapy (66 Gy in 24 fractions weeks 2-6) and cisplatin (6 mg/m2 q1d during weeks 2-6) daily. Early response was monitored using FDG PET/CT-scans performed 4 weeks after treatment and response was evaluated by a CT scan 6 weeks after the last fraction of radiotherapy. RESULTS Between March and July 2008, 12 consecutive patients were enrolled. Ten patients completed protocol treatment. Although generally well tolerated, two patients were unable to complete protocol treatment. Acneiform rash and dysphagia were the most common side effects (grade 53 according to CTCAE v 3.0). No unexpected toxicities were observed. Early response monitoring revealed a metabolic response in 8 (out of 10) patients. The CT scan evaluation showed a partial response in 8 patients. Four (out of 12) patients showed progressive disease after 12 months of follow-up. CONCLUSIONS The addition of cetuximab to CCRT in patients with NSCLC was generally well tolerated and early clinical responses were observed with this new therapy combination. A randomized phase II study comparing CCRT with CCRT and cetuximab is ongoing.

LanguageEnglish
Pages65-71
Number of pages7
JournalEuropean journal of Clinical and Medical Oncology
Volume3
Issue number3
Publication statusPublished - 13 Jul 2011

Keywords

  • Cetuximab
  • Concurrent chemoradiotherapy
  • Egfr
  • Nonsmall cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Schaake, E. E., Aukema, T. S., Belderbos, J. S., Uyterlinde, W., van Zandwijk, N., Váldes Olmos, R. A., ... van den Heuvel, M. M. (2011). Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study. European journal of Clinical and Medical Oncology, 3(3), 65-71.
Schaake, E. E. ; Aukema, T. S. ; Belderbos, J. S. ; Uyterlinde, W. ; van Zandwijk, N. ; Váldes Olmos, R. A. ; Verheij, M. ; Vincent, Andrew ; van den Heuvel, M. M. / Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma : A feasibility study. In: European journal of Clinical and Medical Oncology. 2011 ; Vol. 3, No. 3. pp. 65-71.
@article{3cd2e8e2bcef4908a597e75fdec1d9d0,
title = "Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study",
abstract = "INTRODUCTION Despite the benefits from concurrent chemoradiotherapy (CCRT) regimens in patients with locally advanced non-small cell lung cancer (NSCLC), more efficacious treatment options are needed. Cetuximab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor, has demonstrated activity in patients with metastatic NSCLC. This study assessed whether combining cetuximab with CCRT is feasible. METHODS Patients with inoperable locally advanced NSCLC received cetuximab (400 mg/m2 on day 1, 250 mg/m2 q1w in weeks 2-6) in addition to radiotherapy (66 Gy in 24 fractions weeks 2-6) and cisplatin (6 mg/m2 q1d during weeks 2-6) daily. Early response was monitored using FDG PET/CT-scans performed 4 weeks after treatment and response was evaluated by a CT scan 6 weeks after the last fraction of radiotherapy. RESULTS Between March and July 2008, 12 consecutive patients were enrolled. Ten patients completed protocol treatment. Although generally well tolerated, two patients were unable to complete protocol treatment. Acneiform rash and dysphagia were the most common side effects (grade 53 according to CTCAE v 3.0). No unexpected toxicities were observed. Early response monitoring revealed a metabolic response in 8 (out of 10) patients. The CT scan evaluation showed a partial response in 8 patients. Four (out of 12) patients showed progressive disease after 12 months of follow-up. CONCLUSIONS The addition of cetuximab to CCRT in patients with NSCLC was generally well tolerated and early clinical responses were observed with this new therapy combination. A randomized phase II study comparing CCRT with CCRT and cetuximab is ongoing.",
keywords = "Cetuximab, Concurrent chemoradiotherapy, Egfr, Nonsmall cell lung cancer",
author = "Schaake, {E. E.} and Aukema, {T. S.} and Belderbos, {J. S.} and W. Uyterlinde and {van Zandwijk}, N. and {V{\'a}ldes Olmos}, {R. A.} and M. Verheij and Andrew Vincent and {van den Heuvel}, {M. M.}",
year = "2011",
month = "7",
day = "13",
language = "English",
volume = "3",
pages = "65--71",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
number = "3",

}

Schaake, EE, Aukema, TS, Belderbos, JS, Uyterlinde, W, van Zandwijk, N, Váldes Olmos, RA, Verheij, M, Vincent, A & van den Heuvel, MM 2011, 'Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study', European journal of Clinical and Medical Oncology, vol. 3, no. 3, pp. 65-71.

Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma : A feasibility study. / Schaake, E. E.; Aukema, T. S.; Belderbos, J. S.; Uyterlinde, W.; van Zandwijk, N.; Váldes Olmos, R. A.; Verheij, M.; Vincent, Andrew; van den Heuvel, M. M.

In: European journal of Clinical and Medical Oncology, Vol. 3, No. 3, 13.07.2011, p. 65-71.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma

T2 - European journal of Clinical and Medical Oncology

AU - Schaake, E. E.

AU - Aukema, T. S.

AU - Belderbos, J. S.

AU - Uyterlinde, W.

AU - van Zandwijk, N.

AU - Váldes Olmos, R. A.

AU - Verheij, M.

AU - Vincent, Andrew

AU - van den Heuvel, M. M.

PY - 2011/7/13

Y1 - 2011/7/13

N2 - INTRODUCTION Despite the benefits from concurrent chemoradiotherapy (CCRT) regimens in patients with locally advanced non-small cell lung cancer (NSCLC), more efficacious treatment options are needed. Cetuximab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor, has demonstrated activity in patients with metastatic NSCLC. This study assessed whether combining cetuximab with CCRT is feasible. METHODS Patients with inoperable locally advanced NSCLC received cetuximab (400 mg/m2 on day 1, 250 mg/m2 q1w in weeks 2-6) in addition to radiotherapy (66 Gy in 24 fractions weeks 2-6) and cisplatin (6 mg/m2 q1d during weeks 2-6) daily. Early response was monitored using FDG PET/CT-scans performed 4 weeks after treatment and response was evaluated by a CT scan 6 weeks after the last fraction of radiotherapy. RESULTS Between March and July 2008, 12 consecutive patients were enrolled. Ten patients completed protocol treatment. Although generally well tolerated, two patients were unable to complete protocol treatment. Acneiform rash and dysphagia were the most common side effects (grade 53 according to CTCAE v 3.0). No unexpected toxicities were observed. Early response monitoring revealed a metabolic response in 8 (out of 10) patients. The CT scan evaluation showed a partial response in 8 patients. Four (out of 12) patients showed progressive disease after 12 months of follow-up. CONCLUSIONS The addition of cetuximab to CCRT in patients with NSCLC was generally well tolerated and early clinical responses were observed with this new therapy combination. A randomized phase II study comparing CCRT with CCRT and cetuximab is ongoing.

AB - INTRODUCTION Despite the benefits from concurrent chemoradiotherapy (CCRT) regimens in patients with locally advanced non-small cell lung cancer (NSCLC), more efficacious treatment options are needed. Cetuximab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor, has demonstrated activity in patients with metastatic NSCLC. This study assessed whether combining cetuximab with CCRT is feasible. METHODS Patients with inoperable locally advanced NSCLC received cetuximab (400 mg/m2 on day 1, 250 mg/m2 q1w in weeks 2-6) in addition to radiotherapy (66 Gy in 24 fractions weeks 2-6) and cisplatin (6 mg/m2 q1d during weeks 2-6) daily. Early response was monitored using FDG PET/CT-scans performed 4 weeks after treatment and response was evaluated by a CT scan 6 weeks after the last fraction of radiotherapy. RESULTS Between March and July 2008, 12 consecutive patients were enrolled. Ten patients completed protocol treatment. Although generally well tolerated, two patients were unable to complete protocol treatment. Acneiform rash and dysphagia were the most common side effects (grade 53 according to CTCAE v 3.0). No unexpected toxicities were observed. Early response monitoring revealed a metabolic response in 8 (out of 10) patients. The CT scan evaluation showed a partial response in 8 patients. Four (out of 12) patients showed progressive disease after 12 months of follow-up. CONCLUSIONS The addition of cetuximab to CCRT in patients with NSCLC was generally well tolerated and early clinical responses were observed with this new therapy combination. A randomized phase II study comparing CCRT with CCRT and cetuximab is ongoing.

KW - Cetuximab

KW - Concurrent chemoradiotherapy

KW - Egfr

KW - Nonsmall cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=79960084447&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 65

EP - 71

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 3

ER -